Policy and market dynamics are rapidly evolving in biotech. The U.S. Department of Health and Human Services submitted a proposed rule to introduce a Most-Favored-Nation (MFN) prescription drug pricing model, aiming to contain costs, with the White House reviewing the initiative. Meanwhile, Claritas Rx unveiled Access Analytics, a platform streamlining market access operations by integrating payer and distribution data for more rapid, actionable insights. These developments reflect growing efforts to enhance affordability and access in biotech therapeutics.